Long-term efficacy of (90)Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms.

about

Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors.

P2860

Q38769465-E8A19BF8-B6AE-4470-843E-992ADF385200

P2860

Long-term efficacy of (90)Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms.

Item

http://www.wikidata.org/entity/Q38870046

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Long-term efficacy of (90)Y-DO ...... owel neuroendocrine neoplasms.

@en

type

Item

label

Long-term efficacy of (90)Y-DO ...... owel neuroendocrine neoplasms.

@en

prefLabel

Long-term efficacy of (90)Y-DO ...... owel neuroendocrine neoplasms.

@en

P1476

Long-term efficacy of (90)Y-DO ...... bowel neuroendocrine neoplasms

@en

P2093

Anna Lewczuk

http://www.w3.org/2001/XMLSchema#string

Artur Sankowski

http://www.w3.org/2001/XMLSchema#string

John R Buscombe

http://www.w3.org/2001/XMLSchema#string

Nina Seklecka

http://www.w3.org/2001/XMLSchema#string

Wojciech Rogowski

http://www.w3.org/2001/XMLSchema#string

P2860

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.

Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.

Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives.

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS).

Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours

Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours.

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).

Lutetium-labelled peptides for therapy of neuroendocrine tumours.

P304

1877-1885

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2016-0031

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jaroslaw Cwikla

Ewa Wachuła

P577

2016-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27156864

http://www.w3.org/2001/XMLSchema#string

Long-term efficacy of (90)Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms.

about

P2860

P2860

Long-term efficacy of (90)Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698